Вопрос — ответ
- Misselwitz B, Butter M, Verbeke K, Fox MR. Update on lactose malabsorption and intolerance: pathogenesis, diagnosis and clinical management. Gut. 2019 Nov;68(11):2080-2091. doi: 10.1136/gutjnl-2019-318404. Epub 2019 Aug 19. PMID: 31427404; PMCID: PMC6839734
- Suarez FL, Zumarraga LM, Furne JK, Levitt MD. Nutritional supplements used in weight-reduction programs increase intestinal gas in persons who malabsorb lactose. J Am Diet Assoc. 2001 Dec;101(12):1447-52. doi: 10.1016/S0002-8223(01)00349-2. PMID: 11762740
- Bischoff SC, Damms-Machado A, Betz C, Herpertz S, Legenbauer T, Löw T, Wechsler JG, Bischoff G, Austel A, Ellrott T. Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life - a prospective study. Int J Obes (Lond). 2012 Apr;36(4):614-24. doi: 10.1038/ijo.2011.107. Epub 2011 Jun 14. PMID: 21673653; PMCID: PMC3322430
- Steven S, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. Diabetes Care. 2016 May;39(5):808-15. doi: 10.2337/dc15-1942. Epub 2016 Mar 21. Erratum in: Diabetes Care. 2018 Jun;41(6):1321. doi: 10.2337/dc18-er06. PMID: 27002059
- Ard JD, Neeland IJ, Rothberg AE, Chilton RJ, de Luis D, Cohen SS, Johansen OE. The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study. Diabetes Obes Metab. 2024 Mar;26(3):950-960. doi: 10.1111/dom.15392. Epub 2023 Dec 11. PMID: 38073426
Где купить
